Floatz logo

Trastuzumab Deruxtecan

Triple-Negative Breast Carcinoma

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →
metastatic malignant neoplasm in the brainActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →